晚期食管癌二线化疗药物的研究进展

Progress of second-line chemotherapy of advanced esophageal cancer

食管癌是我国常见高发恶性肿瘤之一,大部分患者确诊时已发生局部侵犯或远处转移,而姑息性化疗是晚期食管癌患者的主要治疗手段。一线化疗后疾病进展且一般状况良好的患者仍需要接受二线治疗,然而目前尚无标准的二线化疗方案,故寻找一线化疗失败后的解救治疗方案就显得尤其的重要。近十多年来,许多新药包括多西紫杉醇、伊立替康及吉西他滨等已被试验用于晚期食管癌的化疗,而随着分子靶向药物的进步,也为食管癌的内科治疗提供了新的治疗途径。

High incidence of esophageal cancer is one of our common,most patients are diagnosed when local invasion or distant metastasis occurred,and palliative chemotherapy in patients with advanced esophageal cancer is the main treatment.Patients who have disease progression after first-line chemotherapy,are generally in good condition and still in need of second-line chemotherapy,however,there is no standard second-line treatment,so looking for rescue after failed first-line chemotherapy treatment becomes more and more important.In the recent decade,various new agents have been tested in the chemotherapy of advanced esophageal cancer,including docetaxel,irinotecan,and gemcitabine and so on.With the advancement of molecular targeted drugs,those drugs provide a new therapeutic approach to medical treatment of esophageal cancer.